NSRX

TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the Company’s management will present live at the Zacks Life Sciences Investor Forum hosted by VirtualInvestorConferences.com, to be held virtually on June 24-25, 2026. The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. Nasus invites individual and institutional investors, as well as advisors and

4 - Nasus Pharma Ltd (0002029039) (Issuer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study in Third Quarter of 2026 TEL AVIV, Israel, June 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a preclinical pharmacokinetic ("PK") and safety study of NS003, the Company's proprietary intranasal powder formulation of ondansetron being developed for chemotherapy and post-operative nausea and vomiting. Ondanse

TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, June 10, 2026 at 8:00 AM ET featuring Michael S. Blaiss, MD (Medical College of Georgia, Good Samaritan Health Center of Gwinnett) and Joel Brooks, DO, MPH (Columbia University Vagelos College of Physicians and Surgeons, New York-Presbyterian Morgan Stanley Children's Hospital), who will join members of the Company's management to discuss the unmet need and current treatment landscape

S-8 - Nasus Pharma Ltd (0002029039) (Filer)

SCHEDULE 13G - Nasus Pharma Ltd (0002029039) (Subject)

TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company management will participate in upcoming investor conferences.  Market Movers Investor SummitMay 5, 2026, New York, NYChief Financial Officer Eyal Rubin will participate in 1x1 meetings.  D. Boral Capital Global ConferenceMay 7, 2026, New York, NYChief Financial Officer Eyal Rubin will participate in 1x1 meetings.  Interested investors should contact their respective representatives at the sponsoring institutions to request meetings. About Nasu

4 - Nasus Pharma Ltd (0002029039) (Issuer)

SCHEDULE 13G - Nasus Pharma Ltd (0002029039) (Subject)

4 - Nasus Pharma Ltd (0002029039) (Issuer)

EFFECT - Nasus Pharma Ltd (0002029039) (Filer)

3 - Nasus Pharma Ltd (0002029039) (Issuer)

3 - Nasus Pharma Ltd (0002029039) (Issuer)

3 - Nasus Pharma Ltd (0002029039) (Issuer)

3 - Nasus Pharma Ltd (0002029039) (Issuer)

3 - Nasus Pharma Ltd (0002029039) (Issuer)

3 - Nasus Pharma Ltd (0002029039) (Issuer)

3 - Nasus Pharma Ltd (0002029039) (Issuer)

3 - Nasus Pharma Ltd (0002029039) (Issuer)

POS AM - Nasus Pharma Ltd (0002029039) (Filer)

6-K - Nasus Pharma Ltd (0002029039) (Filer)

20-F - Nasus Pharma Ltd (0002029039) (Filer)

Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study planned for Q4 2026 Company advancing pipeline assets NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic) toward first-in-human studies expected to start in the second half of 2026, significantly expanding the Company's intranasal product portfolio into additional high value therapeutic areas Company well funded through planned NS002 pivotal study and potential NDA submission TEL AVIV, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSR

In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis. The study demonstrated a statistically significant and clinically meaningful advantage over EpiPen in time to therapeutic threshold (T100), with NS002 reaching effective epinephrine levels in a median of 1.69 minutes compared to 3.42 minutes for EpiPen. At 2.5 minutes, 67.4% of participants receiving NS002 had already reached therapeutic levels versus 27.1% with EpiPen, with the advantage persisting through the 5-minute mark. Across the critical early treatment wind